Hypereosinophilia (HE) in acute myeloid leukemia (AML) with normal karyotype: A report of two cases

We present two rare cases of hypereosinophilia (HE) in acute myeloid leukemia with normal karyotype (NK-AML) at diagnosis. The first case is a 29-year-old female who presented with HE. On evaluation, she was found to have NK-AML. She failed to achieve complete remission (CR) after the first induction therapy with standard idarubicin and cytarabine (IA). She achieved CR after two cycles of reinduction chemotherapy with cytarabine, aclarubicin, and granulocyte colony-stimulating factor (G-CSF) (CAG) but had early relapsed. Reinduction chemotherapy with fludarabine, Ara-C, and G-CSF (FLAG) led to her second remission, followed by unrelated umbilical cord hematopoietic stem cell transplantation (HSCT). Unfortunately, she died of thrombotic thrombocytopenic purpura. The second case is a 23-year-old male who was diagnosed as NK-AML with HE. IA regimen was successively used in two cycles treatment achieving CR. He underwent haploidentical HSCT but had a relapse after 17 months of sustained remission and died 4 months later. The presence of HE may be a poor prognostic feature in NK-AML.
Source: Nigerian Journal of Clinical Practice - Category: Rural Health Authors: Source Type: research

Related Links:

This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patien ts for whom, overall results remain disappointing.
Source: Annals of Hematology - Category: Hematology Source Type: research
Standardized phase angle (SPhA) is a tool used to estimate body composition and cell membrane integrity. Lower baseline SPhA was associated with increased incidence of 60 ‐day mortality in univariable (odds ratio [OR] = 5.25; 1.35, 20.44;P = .02) but not multivariable analysis (OR = 3.12; 0.67, 14.48;P = .15) adjusted for age, creatinine, and cytogenetics. Standardized phase angle is a rapid, noninvasive, and objective measure that may be used to inform risk stratification in adult acute leukemia patients. AbstractStandardized phase angle (SPhA) is a tool used to estimate body comp...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract New therapeutic strategies are needed for pediatric acute myeloid leukemia to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric patients with newly diagnosed acute myeloid leukemia. AAML1031 randomized patients younger than 30 years of age with de novo acute myeloid leukemia to standard treatment with or without bortezomib. All patients received the identical chemotherapy backbone with either four intensive chemotherapy courses or three courses f...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
AbstractPurpose of reviewTo discuss the approach to antifungal prophylaxis and treatment for invasive aspergillosis in immunocompromised patients with hematologic malignancies, hematopoietic stem cell transplant, and solid organ transplant recipients.Recent findingsPrimary prophylaxis againstAspergillus is recommended for patients with acute myelogenous leukemia receiving remission-induction chemotherapy. Posaconazole or voriconazole are appropriate antifungal agents. A new formulation of itraconazole (SUBA-itraconazole) is an alternative option. Breakthrough infections on isavuconazole prophylaxis have been recently repor...
Source: Current Treatment Options in Infectious Diseases - Category: Infectious Diseases Source Type: research
Acute myeloid leukemia bearing a RUNX1 gene mutation (RUNX1+ AML) has been proposed as a provisional entity in the 2016 WHO classification. Clinically, it has been associated with inferior response rates and outcome after conventional chemotherapy. Accordingly, RUNX1+ AML is allocated in the unfavorable prognostic category of the 2017 European Leukemia Net classification. Following allogeneic stem cell transplantation (alloSCT), RUNX1 was an unfavorable factor in one study in MDS/secondary AML, while data in de novo AML are scarce.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 8 Source Type: research
In QuANTUM-R, the once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefit vs SC (median overall survival [mOS], 6.2 vs 4.7 mo [HR, 0.76 (95% CI, 0.58-0.98); P  = .02]) in R/R FLT3-ITD AML (NCT02039726). Before randomization, 25% (Q) and 23% (SC) of pts had 1 prior HSCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 7 Source Type: research
Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (allo SCT) remains a major therapeutic challenge. While patients with longer remission after initial allo SCT are recommended to receive either 2nd allo SCT or donor lymphocyte infusion (2nd allo SCT/DLI), survival probability for patients relapsing within 6 months of SCT are dismal. We evaluated the outcomes of AML relapse after allo SCT to assess the impact of 2nd allo SCT/DLI on long term survival.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 133 Source Type: research
ConclusionsMIDO represents a clinically significant advancement in the management of newly diagnosed FLT3-mutated AML. In this analysis, MIDO add-on therapy showed gains in LYs and QALYs versus SOC alone and was found to be a cost-effective option at a €100,000 per QALY threshold for end-of-life treatment.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
Purpose of review Despite advances in therapy over the past decades, overall survival for children with acute myeloid leukemia (AML) has not exceeded 70%. In this review, we highlight recent insights into risk stratification for patients with pediatric AML and discuss data driving current and developing therapeutic approaches. Recent findings Advances in cytogenetics and molecular profiling, as well as improvements in detection of minimal residual disease after induction therapy, have informed risk stratification, which now relies heavily on these elements. The treatment of childhood AML continues to be based primaril...
Source: Current Opinion in Pediatrics - Category: Pediatrics Tags: HEMATOLOGY AND ONCOLOGY: Edited by Brigitte Widemann Source Type: research
AbstractQuizartinib is a tyrosine kinase inhibitor selectively targeting the FMS-like tyrosine kinase 3 (FLT3) receptor that has been developed for the treatment of acute myeloid leukaemia (AML). The Phase 3 QuANTUM-R study investigated the efficacy of quizartinib monotherapy in patients with relapsed/refractoryFLT3-ITD mutation-positive AML. The clinical course of four QuANTUM-R participants exemplifies issues specific to quizartinib treatment and is described here. Patient 1 wasFLT3-ITD mutation-negative at AML diagnosis, but becameFLT3-ITD mutation-positive during treatment that included several lines of chemotherapy an...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Leukemia | Nigeria Health | Rural Health | Stem Cell Therapy | Stem Cells | Transplants